keyword
MENU ▼
Read by QxMD icon Read
search

colorectal cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/28106826/colorectal-carcinoma-a-general-overview-and-future-perspectives-in-colorectal-cancer
#1
REVIEW
Inés Mármol, Cristina Sánchez-de-Diego, Alberto Pradilla Dieste, Elena Cerrada, María Jesús Rodriguez Yoldi
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death. Most cases of CRC are detected in Western countries, with its incidence increasing year by year. The probability of suffering from colorectal cancer is about 4%-5% and the risk for developing CRC is associated with personal features or habits such as age, chronic disease history and lifestyle. In this context, the gut microbiota has a relevant role, and dysbiosis situations can induce colonic carcinogenesis through a chronic inflammation mechanism...
January 19, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28105616/-interpretation-of-the-updates-of-nccn-2017-version-1-0-guideline-for-colorectal-cancer
#2
Gong Chen
The NCCN has recently released its 2017 version 1.0 guideline for colorectal cancer. There are several updates from this new version guideline which are believed to change the current clinical practice. Update one, low-dose aspirin is recommended for patients with colorectal cancer after colectomy for secondary chemoprevention. Update two, biological agents are removed from the neoadjuvant treatment regimen for resectable metastatic colorectal cancer (mCRC). This update is based on lack of evidence to support benefits of biological agents including bevacizumab and cetuximab in the neoadjuvant setting...
January 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28105361/computed-tomograpy-evaluation-of-morphological-changes-clinical-response-and-survival-in-colorectal-cancer-liver-metastasis-treated-by-regorafenib-a-case-report
#3
Nobuhisa Matsuhashi, Takao Takahashi, Junko Kato, Toshiyuki Tanahashi, Satoshi Matsui, Yoshiyuki Sasaki, Hisashi Imai, Yoshihiro Tanaka, Naoki Okumura, Kazuya Yamaguchi, Manabu Futamura, Shinji Osada, Kazuhiro Yoshida
Pathological response to preoperative chemotherapy was recently found to be correlated with improved survival and has been proposed as a new outcome end-point following resection of liver metastases from colorectal cancer (CRC). It was demonstrated that, particularly after therapy with bevacizumab, CRC liver metastases decreased in size and underwent distinct morphological changes on computed tomography (CT). However, morphological changes in response to treatment with regorafenib have not yet been reported...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28103302/crude-extracts-flavokawain-b-and-alpinetin-compounds-from-the-rhizome-of-alpinia-mutica-induce-cell-death-via-uck2-enzyme-inhibition-and-in-turn-reduce-18s-rrna-biosynthesis-in-ht-29-cells
#4
Ibrahim Malami, Ahmad Bustamam Abdul, Rasedee Abdullah, Nur Kartinee Bt Kassim, Rozita Rosli, Swee Keong Yeap, Peter Waziri, Imaobong Christopher Etti, Muhammad Bashir Bello
Uridine-cytidine kinase 2 is an enzyme that is overexpressed in abnormal cell growth and its implication is considered a hallmark of cancer. Due to the selective expression of UCK2 in cancer cells, a selective inhibition of this key enzyme necessitates the discovery of its potential inhibitors for cancer chemotherapy. The present study was carried out to demonstrate the potentials of natural phytochemicals from the rhizome of Alpinia mutica to inhibit UCK2 useful for colorectal cancer. Here, we employed the used of in vitro to investigate the effectiveness of natural UCK2 inhibitors to cause HT-29 cell death...
2017: PloS One
https://www.readbyqxmd.com/read/28102464/a-phase-i-and-pharmacokinetic-study-of-afilbercept-with-folfiri-comparison-of-chinese-and-caucasian-populations
#5
Jianming Xu, Yingxin Li, Xing Sun, Dongsheng Zhang, Rongrui Liu, Samira Ziti-Ljajic, Dongmei Shi, Fengying Xue, Nathalie Le Bail, Ruihua Xu
Background This study assessed the preliminary safety, pharmacokinetics (PK) and anti-tumor effects of aflibercept in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in Chinese patients with previously-treated advanced solid malignancies. Patients and Methods This open-label single-arm Phase I study conducted at two centers in China included adult (≥18 years) patients with metastatic or unresectable solid malignancies who had received ≥1 prior treatment. Patients received aflibercept 4 mg/kg IV on Day 1 followed by FOLFIRI over Days 1 and 2 every 2 weeks, and were assessed for safety, tumor response, PK parameters and immunogenicity...
January 19, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28101205/impact-of-microsatellite-status-on-chemotherapy-for-colorectal-cancer-patients-with-kras-or-braf-mutation
#6
Chi-Jung Huang, Shih-Hung Huang, Chih-Cheng Chien, Henry Hsin-Chung Lee, Shung-Haur Yang, Chun-Chao Chang, Chia-Long Lee
KRAS and BRAF mutations are frequently detected in cases of colorectal cancer (CRC). The microsatellite status of patients with CRC and mutated KRAS/BRAF is important when determining cancer therapy. In the present study, the microsatellite status and genetic polymorphisms of KRAS (codons 12 and 13) and BRAF (V600E) were characterized in CRC tissue. The mismatch repair activity and oncogenic potential of KRAS were assessed by immunoblots from two KRAS-mutated CRC cell lines, SW480 and HCT116, with different microsatellite statuses, following treatment with 5-fluorouracil (5-FU) and oxaliplatin...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28100854/the-role-of-cancer-stem-cells-in-pathogenesis-of-colorectal-cancer
#7
Magdalena Szaryńska, Agata Olejniczak, Zbigniew Kmieć
Colorectal cancer (CRC) is the third most commonly diagnosed cancer, accounting for about 10% of total adult malignancies worldwide. The majority of CRC cases are diagnosed at the late stage; thus the investigation of the pathogenesis of early-stage disease and its detection could prevent formation of metastasis, a leading cause of death. This review highlights the recent progress in the understanding of the development of cancer stem cells (CSCs) in the colon epithelium and mechanisms of their proliferation...
December 31, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/28100684/association-between-poorly-differentiated-clusters-and-efficacy-of-5-fluorouracil-based-adjuvant-chemotherapy-in-stage-iii-colorectal-cancer
#8
Yosuke Tajima, Yoshifumi Shimada, Hitoshi Kameyama, Ryoma Yagi, Takuma Okamura, Takashi Kobayashi, Shin-Ichi Kosugi, Toshifumi Wakai
OBJECTIVE: Although poorly differentiated cluster has been reported to be a useful grading system for predicting prognosis in colorectal cancer, its relationship to chemotherapy efficacy has not been demonstrated. We aimed to investigate the association between poorly differentiated cluster and the efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer. METHODS: This retrospective study enrolled 131 patients with stage III colorectal cancer who underwent curative resection: 72 received 5-fluorouracil-based adjuvant chemotherapy (chemotherapy group) and 59 did not (surgery-alone group)...
January 17, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28100061/outpatient-palliative-care-and-aggressiveness-of-end-of-life-care-in-patients-with-metastatic-colorectal-cancer
#9
Si Won Lee, Hyun Jung Jho, Ji Yeon Baek, Eun Kyung Shim, Hyun Mi Kim, Ji Yeon Ku, Eun Jung Nam, Yoon-Jung Chang, Hye Jin Choi, Sun Young Kim
BACKGROUND: Palliative care in outpatient setting has been shown to promote better symptom management and transition to hospice care among patients with advanced cancer. Nevertheless, specialized palliative care is rarely provided at cancer centers in Korea. Herein, we aimed to assess aggressiveness of end-of-life care for patients with metastatic colorectal cancer according to the use of outpatient palliative care (OPC) at a single cancer center in Korea. METHODS: We performed a retrospective medical record review for 132 patients with metastatic colorectal cancer who died between 2011 and 2014...
January 1, 2017: American Journal of Hospice & Palliative Care
https://www.readbyqxmd.com/read/28099361/the-cardiotoxicity-of-cetuximab-as-single-therapy-in-chinese-chemotherapy-refractory-metastatic-colorectal-cancer-patients
#10
Xue-Miao Tang, Hao Chen, Yu Liu, Bin-Lian Huang, Xiu-Quan Zhang, Jian-Mei Yuan, Xia He
The cardiac safety of cetuximab, particularly as single approach, has not been investigated extensively. This trial was designed to evaluate the cardiac safety of cetuximab as salvage monotherapy in Chinese chemotherapy-refractory metastatic colorectal cancer (mCRC) patients.Cetuximab was administrated at an initial dose of 400 mg/mon day 1 (week 1), followed by a maintenance dose of 250 mg/m on day 1 of each 7-day cycle. Electrocardiograph (ECG), routine laboratory tests, and troponin I (TNI) Ultra were performed at baseline, during, and after the cetuximab therapy...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28099153/building-personalized-treatment-plans-for-early-stage-colorectal-cancer-patients
#11
Hung-Hsin Lin, Nien-Chih Wei, Teh-Ying Chou, Chun-Chi Lin, Yuan-Tsu Lan, Shin-Ching Chang, Huann-Sheng Wang, Shung-Haur Yang, Wei-Shone Chen, Tzu-Chen Lin, Jen-Kou Lin, Jeng-Kai Jiang
We developed a series of models to predict the likelihood of recurrence and the response to chemotherapy for the personalized treatment of stage I and II colorectal cancer patients. A recurrence prediction model was developed from 235 stage I/II patients. The model successfully distinguished between high-risk and low-risk groups, with a hazard ratio of recurrence of 4.66 (p < 0.0001). More importantly, the model was accurate for both stage I (hazard ratio = 5.87, p = 0.0006) and stage II (hazard ratio = 4...
January 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28088668/near-infrared-light-triggered-drug-delivery-system-for-higher-efficacy-of-combined-chemo-photothermal-treatment
#12
Yi Chen, Haohuan Li, Yueyang Deng, Haifeng Sun, Xue Ke, Tianyuan Ci
: The combination of chemotherapy and photothermal therapy is a promising strategy for cancer treatment. In the present study, indocyanine green (ICG), a widely used near-infrared (NIR) dye in photothermal therapy, and chemotherapeutic drug-doxorubicin (DOX) were loaded within the nanoparticles of novel designed arylboronic ester and cholesterol modified hyaluronic acid (PPE-Chol1-HA), denoted as PCH-DI. We take advantage of reactive oxygen species (ROS) production capability of ICG and ROS-sensitivity of arylboronic ester to realize controllable drug release...
January 11, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/28088319/ercc1-and-ercc2-as-predictive-biomarkers-to-oxaliplatin-based-chemotherapy-in-colorectal-cancer-patients-from-egypt
#13
Amira B Kassem, Salem Eid Salem, Mohamed E Abdelrahim, Amira S A Said, Ahmad Salahuddin, Marwa Mahmoud Hussein, Abeer A Bahnassy
BACKGROUND: The impact of Excision repair cross-complementation group 1 (ERCC1) and group 2 (ERCC2) expression levels on the efficacy of oxaliplatin-based chemotherapy is still controversial. The present study was conducted to determine the predictive value of these molecular biomarkers in stage III and IV colorectal cancer (CRC) patients receiving oxaliplatin (OX)-based chemotherapy as first-line treatment. METHODS: The study included 80 CRC patients who received first line oxaliplatin based chemotherapy The expression levels of ERCC1 and ERCC2-mRNA and proteins were determined in the primary tumors by quantitative real time reverse transcription polymerase chain reaction(RT-qPCR) and immunohistochemistry (IHC); respectively...
January 12, 2017: Experimental and Molecular Pathology
https://www.readbyqxmd.com/read/28088224/clinical-analysis-of-krukenberg-tumours-in-patients-with-colorectal-cancer-a-review-of-57-cases
#14
K Y Xu, H Gao, Z J Lian, L Ding, M Li, J Gu
BACKGROUND: A Krukenberg tumour (KT) is defined as an ovarian metastasis from a gastrointestinal adenocarcinoma and suggests a terminal condition. This study aimed to identify the prognostic factors affecting the survival of patients with KTs of colorectal origin who receive cytoreductive surgery. METHODS: Medical records of patients who had received cytoreductive surgery and had been pathologically diagnosed with KT of colorectal origin in two centres were reviewed...
January 14, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28081548/serum-ldh-predicts-benefit-from-bevacizumab-beyond-progression-in-metastatic-colorectal-cancer
#15
Federica Marmorino, Lisa Salvatore, Cecilia Barbara, Giacomo Allegrini, Lorenzo Antonuzzo, Gianluca Masi, Fotios Loupakis, Beatrice Borelli, Silvana Chiara, Maria Chiara Banzi, Emanuela Miraglio, Domenico Amoroso, Francesco Dargenio, Andrea Bonetti, Angelo Martignetti, Myriam Paris, Daniela Tomcikova, Luca Boni, Alfredo Falcone, Chiara Cremolini
BACKGROUND: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. METHODS: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy...
January 12, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28081292/the-utility-of-abbreviated-patient-reported-outcomes-for-predicting-survival-in-early-stage-colorectal-cancer
#16
Tina Hsu, Caroline H Speers, Hagen F Kennecke, Winson Y Cheung
BACKGROUND: Patient-reported outcomes (PROs) are increasingly used in clinical settings. Prior research suggests that PROs collected at baseline may be associated with cancer survival, but most of those studies were conducted in patients with breast or lung cancer. The objective of this study was to determine the correlation between prospectively collected PROs and cancer-specific outcomes in patients with early stage colorectal cancer. METHODS: Patients who had newly diagnosed stage II or III colorectal cancer from 2009 to 2010 and had a consultation at the British Columbia Cancer Agency completed the brief Psychosocial Screen for Cancer (PSSCAN) questionnaire, which collects data on patients' perceived social supports, quality of life (QOL), anxiety and depression, and general health...
January 12, 2017: Cancer
https://www.readbyqxmd.com/read/28079003/colorectal-cancer-chemotherapy-the-evolution-of-treatment-and-new-approaches
#17
Rachel M McQuade, Vanesa Stojanovska, Joel C Bornstein, Kulmira Nurgali
Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality. Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above 60%, more than 50% of patients are diagnosed at or beyond stage III when distant metastasis has already occurred, in which case 5 year survival rate drops to 10%. Chemotherapeutic intervention coupled with surgery is the backbone of metastatic CRC treatment and the only means of enhanced survival. For decades following its discovery, an antimetabolite 5-fluorouracil (5-FU) was the only chemotherapeutic agent available to successfully improve 12 month survival in CRC patients...
January 11, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28078982/phytochemicals-a-novel-and-prominent-source-of-anti-cancer-drugs-against-colorectal-cancer
#18
Ravikiran Mahadevappa, Hang Fai Kwok
Colorectal cancer (CRC) is a malignant disease whose incidence and mortality rates are greatly influenced by environmental factors. Under-treatment of CRC such as a poor diagnostic evaluation, less aggressive surgery, less intensive chemotherapy results in metastasizing of the primary tumor cells and recurrence of cancer. Prolonged chemotherapy treatment against cancer is hazardous to the patients, which also limits its use in cancer therapy. Current research in developing a novel anti-cancer agent, direct towards finding a better anti-metastatic and an anti-invasive drug with reduced side effects...
January 12, 2017: Combinatorial Chemistry & High Throughput Screening
https://www.readbyqxmd.com/read/28078133/successful-hepatectomy-for-metastatic-squamous-cell-carcinoma-of-the-anal-canal-a-case-report
#19
Tercia Tarciane Sousa, Bruna do Nascimento Santos, Marcos Belotto, Renata D'Alpino Peixoto
Despite rare, metastatic anal carcinoma confers a poor prognosis. Systemic chemotherapy is the mainstay of treatment for advanced disease while the role of biologics and/or surgical resection of metastatic disease are anecdotal. Compared to isolated liver colorectal or neuroendocrine cancer liver metastases, there is far less experience with resection or nonsurgical local ablative procedures for patients with metastatic anal carcinoma to the liver. We report the case of a 67-year-old woman with metastatic anal carcinoma to the liver who was successfully treated with liver resection and remains free of relapse more than one year later...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28078118/less-than-12-lymph-nodes-in-the-surgical-specimen-after-neoadjuvant-chemo-radiotherapy-an-indicator-of-tumor-regression-in-locally-advanced-rectal-cancer
#20
Jaiprakash Gurawalia, Kapil Dev, Sandeep P Nayak, Vishnu Kurpad, Arun Pandey
BACKGROUND: The number of lymph node retrieved in the surgical specimen is important for tumor staging and has paramount impact on prognosis in colorectal cancer and imitates the adequacy of lymph node surgical clearance. The paucity of lymph node yields in patients undergoing resection after preoperative chemo radiotherapy (CRT) in rectal cancer has seen. Lower total number of lymph nodes in the total mesoractal excision (TME) specimen after CRT, could a marker of better tumor response...
December 2016: Journal of Gastrointestinal Oncology
keyword
keyword
40932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"